Full Title IZABRIGHT-BLADDER01: A Randomized, Open-Label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-Based Chemotherapy for Metastatic Urothelial Cancer in Participants with Disease ...

Cardinale Smith, MD, PhD, Chief Medical Officer, was recognized as one of the hospital and health system Chief Medical Officers to know nationwide by Becker’s Hospital Review. Leaders featured on this ...

You may be reading this because you or someone you care about has nasal cavity or sinus cancer. Learning more can help you get ready to talk with your healthcare provider and understand the next steps ...

MSK Radiation Oncology is proud to be an official training site for the American Brachytherapy Society (ABS) "300 in 10" Initiative.

Reconstructive surgery may be needed after a large tumor is removed. Reconstructive surgery helps to rebuild the area and restore how the throat works. Your surgeon will often take tissue and blood ...

Head and neck cancer and its treatment can change how you look, how you feel, and your quality of life. MSK’s team of experts will help restore function and make you feel like y ...

Radiation therapy works by using high-energy X-rays to kill cancer cells. MSK offers precise radiation therapy that kills throat cancer cells with fewer side effects from radiatio ...

Hosted by the Antibody and BioResource Core Facility ...

This guide will help you understand how throat cancer is diagnosed and what your diagnosis means. Learning as much as you can may help you feel ready to talk with doctors about your care. The ...

Full Title Randomized, Multi-dose, Placebo-controlled Phase 2 Trial of Oral Isoquercetin to Reduce Thrombin Generation in Ovarian Cancer Purpose To learn more about the purpose of this study and to ...

Full Title A Phase 2 Multicohort Trial to Further Characterize the Efficacy and Safety of Ciltacabtagene Autoleucel - CARTITUDE-10 Purpose To learn more about the purpose of this study and to find out ...

Full Title A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer ...